U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 11 - 20 of 511 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as ...
Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor designed for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold fo...
Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Eliglustat, marketed by Genzyme as CERDELGA, is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers (PMs) as dete...
Status:
US Approved Rx (2013)
First approved in 2013

Class (Stereo):
CHEMICAL (ABSOLUTE)



Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) whi...
Status:
US Approved Rx (2014)
First approved in 2013

Class (Stereo):
CHEMICAL (ABSOLUTE)



Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an antidiabetic drug u...
Status:
US Approved Rx (2020)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Fidaxomicin (trade names Dificid, Dificlir in Europe) is the first in a new class of narrow spectrum macrocyclic antibiotic drugs indicated for treatment of Clostridium difficile-associated diarrhea. Lipiarmycin (fidaxomicin), a metabolite of Actinop...
Status:
US Approved Rx (2016)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and being developed as an oral once-daily tablet for the treatment of Type 2 diabetes. Linagliptin was first approved by FDA in 2011 under the trade name Tra...
Status:
US Approved Rx (2021)
First approved in 2010

Class (Stereo):
CHEMICAL (ABSOLUTE)



Carglumic acid is a Carbamoyl Phosphate Synthetase 1 (CPS 1) allosteric modulator. CPS1 is found in the mitochondria and is the first enzyme of the urea cycle, which converts ammonia into urea. Carglumic acid acts as a replacement for NAG in NAGS def...
Status:
US Approved Rx (2023)
First approved in 2009

Class (Stereo):
CHEMICAL (MIXED)



Saxagliptin is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatm...
Status:
US Approved Rx (2016)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults wit...

Showing 11 - 20 of 511 results